CLAIMS
1. An antithrombogenic material comprising:
a coating material containing: a cationic polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and
a base material whose surface is coated with said coating material; wherein
said cationic polymer is covalently bound to said base material;
said anionic compound containing a sulfur atom and having anticoagulant activity is ionically bound to said cationic polymer; and
the average thickness of said coating material is 15 to 400 nm.
2. The antithrombogenic material according to claim 1, wherein the total amount of said anionic compound having anticoagulant activity contained in said coating material as calculated from anti-factor Xa activity is 50 to 1000 mlU/cm .
3. The antithrombogenic material according to claim 1 or 2, wherein the abundance ratio of nitrogen atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface is 6.5 to 9.5 atomic percent.
4. The antithrombogenic material according to any one of claims 1 to 3, wherein the weight average molecular weight of said cationic polymer is 10,000 to 1,000,000.
5. The antithrombogenic material according to any one of claims 1 to 4, wherein said base material is a polyester-based polymer, and the maximum stress of said antithrombogenic material is not less than 350 MPa.
6. The antithrombogenic material according to any one of claims 1 to 5, wherein

said cationic polymer has a positively charged functional group, and said base material has a negatively charged functional group; and
the abundance ratio of said positively charged functional group to said negatively charged functional group is 8.0 to 30.
7. The antithrombogenic material according to any one of claims 1 to 6, wherein the ratio of the abundance of said negatively charged functional group in said base material after the covalent bonding of said cationic polymer to the abundance of said negatively charged functional group in said base material before the covalent bonding of said cationic polymer is not more than 25%.
8. The antithrombogenic material according to any one of claims 1 to 7, having cellular adhesiveness.
9. A medical tool comprising the antithrombogenic material according to any one of claims 1 to 8.